PortfoliosLab logoPortfoliosLab logo

Documentation

Upgrade your plan
GERM vs. ARKG
Performance
Return for Risk
Dividends
Drawdowns
Volatility

GERM vs. ARKG

Last updated Apr 2, 2026

Compare and contrast key facts about Amplify Treatments, Testing and Advancements ETF (GERM) and ARK Genomic Revolution Multi-Sector ETF (ARKG).

GERM and ARKG are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. GERM is a passively managed fund by Amplify that tracks the performance of the Prime Treatments, Testing and Advancements Index. It was launched on Jun 17, 2020. ARKG is an actively managed fund by ARK. It was launched on Oct 31, 2014.

Performance

GERM vs. ARKG - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Amplify Treatments, Testing and Advancements ETF (GERM) and ARK Genomic Revolution Multi-Sector ETF (ARKG). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

GERM vs. ARKG - Yearly Performance Comparison

2026 (YTD)20252024
GERM
Amplify Treatments, Testing and Advancements ETF		0.00%0.00%0.00%
ARKG
ARK Genomic Revolution Multi-Sector ETF		-6.49%23.04%-2.87%

Returns By Period

GERM

1D
0.00%
1M
0.00%
YTD
0.00%
6M
0.00%
1Y
0.00%
3Y*
—
5Y*
—
10Y*
—

ARKG

1D
2.54%
1M
-9.43%
YTD
-6.49%
6M
-6.10%
1Y
34.11%
3Y*
-3.42%
5Y*
-21.16%
10Y*
4.95%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Amplify Treatments, Testing and Advancements ETF

ARK Genomic Revolution Multi-Sector ETF

Often compared with GERM:
GERM vs. SBIOGERM vs. EQRRGERM vs. GDOCGERM vs. MDEVGERM vs. BTECGERM vs. MNY.TOGERM vs. PSCH
Often compared with ARKG:
ARKG vs. ARKKARKG vs. XBIARKG vs. IBBARKG vs. GNOMARKG vs. IDNAARKG vs. ARKQARKG vs. ARKW

GERM vs. ARKG - Expense Ratio Comparison

GERM has a 0.68% expense ratio, which is lower than ARKG's 0.75% expense ratio.

ARKG
ARK Genomic Revolution Multi-Sector ETF
GERM
Amplify Treatments, Testing and Advancements ETF

Return for Risk

GERM vs. ARKG — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.
GERM
ARKG
ARKG Risk / Return Rank: 4040
Overall Rank
ARKG Sharpe Ratio Rank: 3939
Sharpe Ratio Rank
ARKG Sortino Ratio Rank: 4949
Sortino Ratio Rank
ARKG Omega Ratio Rank: 3737
Omega Ratio Rank
ARKG Calmar Ratio Rank: 4141
Calmar Ratio Rank
ARKG Martin Ratio Rank: 3333
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GERM vs. ARKG - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Amplify Treatments, Testing and Advancements ETF (GERM) and ARK Genomic Revolution Multi-Sector ETF (ARKG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

GERM vs. ARKG - Sharpe Ratio Comparison

Loading graphics...

Sharpe Ratios by Period

GERMARKGDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

—

0.77

—

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

—

-0.47

—

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

—

0.12

—

Sharpe Ratio (All Time)

Calculated using the full available price history

—

0.08

—

Dividends

GERM vs. ARKG - Dividend Comparison

Neither GERM nor ARKG has paid dividends to shareholders.

TTM202520242023202220212020201920182017
GERM
Amplify Treatments, Testing and Advancements ETF		0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
ARKG
ARK Genomic Revolution Multi-Sector ETF		0.00%0.00%0.00%0.00%0.00%0.62%0.85%3.14%0.82%1.34%

Drawdowns

GERM vs. ARKG - Drawdown Comparison

The maximum GERM drawdown since its inception was 0.00%, smaller than the maximum ARKG drawdown of -83.59%. Use the drawdown chart below to compare losses from any high point for GERM and ARKG.

Loading graphics...

Drawdown Indicators

GERMARKGDifference

Max Drawdown

Largest peak-to-trough decline

0.00%

-83.59%

+83.59%

Max Drawdown (1Y)

Largest decline over 1 year

0.00%

-27.51%

+27.51%

Max Drawdown (5Y)

Largest decline over 5 years

—

-80.18%

—

Max Drawdown (10Y)

Largest decline over 10 years

—

-83.59%

—

Current Drawdown

Current decline from peak

0.00%

-75.76%

+75.76%

Average Drawdown

Average peak-to-trough decline

0.00%

-35.32%

+35.32%

Ulcer Index

Depth and duration of drawdowns from previous peaks

0.00%

10.24%

-10.24%

Volatility

GERM vs. ARKG - Volatility Comparison

The current volatility for Amplify Treatments, Testing and Advancements ETF (GERM) is 0.00%, while ARK Genomic Revolution Multi-Sector ETF (ARKG) has a volatility of 13.41%. This indicates that GERM experiences smaller price fluctuations and is considered to be less risky than ARKG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Loading graphics...

Volatility by Period

GERMARKGDifference

Volatility (1M)

Calculated over the trailing 1-month period

0.00%

13.41%

-13.41%

Volatility (6M)

Calculated over the trailing 6-month period

0.00%

31.90%

-31.90%

Volatility (1Y)

Calculated over the trailing 1-year period

0.00%

44.84%

-44.84%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

0.00%

45.39%

-45.39%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

0.00%

40.94%

-40.94%